Register for our free email digests:
Latest From Sirtris Pharmaceuticals Inc.
Navitor Pharmaceuticals Inc.’s drug discovery efforts are focused on producing compounds that can selectively dampen or bolster mTORC1 activity. Increased activity of mTORC1 has been linked to metabolic, autoimmune, neurodegenerative, and chronic inflammatory diseases.
Armed with cash from a robust M&A and a stock market boom, mutual and hedge funds are eagerly crossing over into mezzanine rounds for private biotechs and playing key roles in some of the year’s biggest venture financings.
Traditional life-science venture is shrinking, leaving gaps for others to fill. Crossover investors are now more creative and aggressive in reaching out to the best private companies. They often seek out entrepreneurs with glittering track records of repeat success, and some crossover investors also join mezzanine rounds to familiarize themselves with an interesting new company, management team, or technology earlier and at a lower cost than on the public markets.
Corporate venture capital groups have made an impact on life science investing in recent years, but when it comes to going public, the biotechs they back aren’t seeing an extra boost.
- Controlled Release
- Site Specific
- Drug Delivery
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Otonomy Inc.
- Senior Management
David Weber, PhD, Pres. & CEO
Paul Cayer, CFO & CBO
Kathie M Bishop, PhD, CSO
Anthony J Yost, Chief Commercial Officer
Dean Hakanson, MD, CMO
Robert M Savel, CTO
- Contact Info
Phone: (858) 242-5200
6275 Nancy Ridge Dr.
San Diego, CA 92121
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.